Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
Takeda Pharmaceutical and Teva Pharmaceutical Industries Ltd. have clinched an accord to set up a generic joint venture in Japan, the two companies said on November 30.The joint company, which is scheduled to launch operations in April-June 2016, will be…
To read the full story
Related Article
BUSINESS
- Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
- Sumitomo Flags Diabetes Pipeline Gap as Key Strategic Issue: CEO
February 2, 2026
- Astellas, MSD Seek Japan Nod for Padcev/Keytruda in Perioperative MIBC
February 2, 2026
- Alfresa Launches End-to-End Platform to Support Biotech Entry into Japan
February 2, 2026
- Nichi-Iko’s Xarelto Generic Adds VTE Use
February 2, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…